chemotherapy drugs

In chemotherapy treatment the entire body is affected in one way or another. Unfortunately a align effect of this treatment is hair loss. Chemotherapy is carried out by administering drugs that are designed to kill cancerous cells. These drugs are injected right into the vein or muscle create from raw material. The drugs flow through the blood stream. Because of this systematic treatment the drugs cannot be taken orally. Since there are several types of chemotherapy drugs align effects can vary. These drugs generally affect rapidly dividing cells. Mostly affected are daub cells. It's important to say that these cells primarily job is to fight infection displace oxygen to other areas of the be and help change state blood. Cancer patients will be more exposed to infections discharge easily and change state more fatigued. One side cause for some chemotherapy drugs is thinning hair. It's also possible that that you could lose your hair all together depending on the drugs used. Some populate act this kind of hair loss very seriously which is understandable because it's so noticeable and not easy to hide. It's a good idea to understand the implications of chemotherapy induced hair loss before it happens. This ordain make the transition easier down the road. Depression is often a byproduct of chemotherapy and hair loss in cancer patients. It's sometimes difficult to deal with the helplessness and embarrassment of the situation. It's never easy for friends and family either. Cancer no matter what write is always serous and often times hereditary. Women usually have a much a more difficult measure dealing with this type of hair loss then men do since a woman's hair is usually a part of her personally and pride. Through this difficult time it's important to never lose hope. Sometimes the beat way to deal with the situation is positive thinking. Positive thinking can sometimes lead us through the darkest times even when things seem hopeless.

Forex Groups - Tips on Trading

Related article:
http://cancer--treatment.blogspot.com/2007/10/chemotherapy-treatment-and-hair-loss.html

comments | Add comment | Report as Spam

In chemotherapy treatment the entire body is affected in one way or another. Unfortunately a side effect of this treatment is hair loss. Chemotherapy is carried out by administering drugs that are designed to blackball cancerous cells. These drugs are injected alter into the vein or muscle tissue. The drugs flow through the blood be adrift. Because of this systematic treatment the drugs cannot be taken orally. Since there are several types of chemotherapy drugs align effects can vary. These drugs generally affect rapidly dividing cells. Mostly affected are blood cells. It's important to note that these cells primarily job is to contend infection displace oxygen to other areas of the body and back up clot blood. Cancer patients ordain be more exposed to infections bleed easily and change state more fatigued. One align effect for some chemotherapy drugs is thinning hair. It's also possible that that you could lose your hair all together depending on the drugs used. Some people take this kind of hair loss very seriously which is understandable because it's so noticeable and not easy to hide. It's a good idea to understand the implications of chemotherapy induced hair loss before it happens. This ordain alter the transition easier down the road. Depression is often a byproduct of chemotherapy and hair loss in cancer patients. It's sometimes difficult to deal with the helplessness and embarrassment of the situation. It's never easy for friends and family either. Cancer no matter what write is always serous and often times hereditary. Women usually undergo a much a more difficult measure dealing with this write of hair loss then men do since a woman's hair is usually a part of her personally and pride. Through this difficult time it's important to never lose hope. Sometimes the beat way to deal with the situation is positive thinking. Positive thinking can sometimes lead us through the darkest times even when things be hopeless.

Forex Groups - Tips on Trading

Related article:
http://cancer--treatment.blogspot.com/2007/10/chemotherapy-treatment-and-hair-loss.html

comments | Add comment | Report as Spam

When I was a kid and I got sick my Mom would take me to see the family Doctor who would always tell me to stick out my tongue and say "ahhhh" check for swollen glands in my neck take my temperature and then send me home with a lollipop and a prescription for an antibiotic..... all better 10 days later!So this being sick and not being able to just "get better" in 10 days is hard for me to cope with. Why can't I just take a pill twice a day for 10 days and be all better now? I thought my childhood Doctor could cure me of everything...... the scared little girl that still lives hidden deep inside of me wishes Dr. Pelic was still alive still believes he could of made me all better. Fast forward 40 something years and I can't seem to catch a break with any of the meds I have been on......1st round 8 weeks of AC & T Now I just read an article that Taxol does Nothing for ER/PR positive Breast Cancer..... great! Then my 2nd round of new chemo was Xeloda... Easy to take pill form taken at home but the longer I was on it the sicker and more weak I became where I lost all my strength due to the fact I was either too sick to eat or sleeping my life away. Then we tried another chemo cocktail of Gemzar and Carboplatin And this one is the worse yet. I'm still getting sick to my stomach almost 2 weeks after my treatment not eating will soon make me weak again and unable to get around on my own. I see Dr. Serious on Tuesday. We already tried the full dose (puke) we tried the half dose (much milder but is it still effective?) I'm going to see about a 2/3rd dose or trying something completely different. I can't spend my life looking into the bottom of my toilet bowl! I can't even keep down the Zofran (anti sickness medicine ) most times. How much my world has changed. If I didn't take this cancer one day at a time I think I would of given up a long time ago. I'm tired but most of all I am sick of being sick. Now lets break it down...... I find my lump early enough stage 2B breast cancer. I have the breast removed. I have a tram flap reconstruction. I do my 8 weeks of AC & T. I start my hormone therapy of tomaxifen. I get the all clear even without any further testing and 3 months later I'm told I now have cancer in my lungs,my liver my brain and my spine... now it's called stage IV breast cancer. no longer curable only treatable and I will be a cancer patient the rest of my life.... after reading all the above kinda makesya wonder if you want to be a cancer patient the rest of your life. Chronically ill people are a tough breed we dig deep inside for what is worth fighting for and we fight for it and sometimes do we let our mind wander to the otherside. Tomorrow's a new day! I'll be around to see it! You never fail to amaze me...... no matter what is thrown at you and how bad you feel you still have that stubboness that fails to give in.... Thats what i love about you. You are an inspiration to others with this dreadful disease. Keep battling Kim........ Hugs Jayne my bff Hayley from camp told me something for people who survied cancer it is "Don`t tell me the sky is the limit when there r foot prints on the moon". Even though i never met a person who had cancer it inspired me now take this and BELIEVE from the 11 year old Catherine F Dear Kim,Your entry made me cry. You have been in my thoughts ever since you were first diagnosed with this terrible disease. I have read every entry you have made. Like others when I get an alert from you. I always read you first. I just want you to know my thoughts and prayers are with you. I pray God will heal you and make you healthy again. May God bless you. Hugs,Pat

Forex Groups - Tips on Trading

Related article:
http://journals.aol.com/demandnlilchit/Ishavedmylegsforthis/entries/2007/10/14/where-my-head-is-at-today-10-14-07/1576

comments | Add comment | Report as Spam

SAN FRANCISCO. October 24. 2007 /PRNewswire-FirstCall/ -- CellTherapeutics. Inc. (CTI) announced preclinical data presented atthe 19th annual AACR-NCI-EORTC Symposium show its bis-platinatedrug candidates. CT-47613 and CT-47609 kill tumors refractory tocurrently marketed platinum agents carboplatin cisplatin andoxaliplatin. These compounds could register human clinical trials inlate 2008. "Bis-platinates represent a promising new class ofplatinum-based chemotherapy drugs with a potential broad spectrumof anti-tumor activity. Anti-cancer drugs containing platinum are acornerstone therapy for a wide be of tumor types includingovarian testicular colorectal continue and neck and lung cancer,"said Jack W. Singer. M. D.. Chief Medical command of CTI. "Thesebis-platinates unlike the currently approved platinum compounds,contain two platinum atoms and work by binding to and damaging bothstrands of DNA making it much more difficult for cancer cells torepair the damage. The preclinical studies presented at thismeeting suggest these compounds are substantially more active thanthe existing monoplatinates -- especially againstplatinum-resistant tumors. These agents could represent asignificant go in the treatment of a wide variety ofcancers." Scientists from CTI-Europe presented data on two novelbis-platinum complexes. CT-47613 and CT-47609. When tested inanimal models of ovarian cancer and colon cancer thebis-platinates were significantly more potent than the two mostcommonly used platinum based chemotherapy drugs carboplatin andcisplatin and oxaliplatin. Importantly these agents demonstratedpotent anti-tumor activity in tumors with either acquired orintrinsic resistance to cisplatin or carboplatin representing thefirst such class of binuclear platinum based drugs to show activityin these tumor types. While initially effective in treating cancer many tumorsultimately develop resistance to standard platinum agents. Priorattempts at developing tri-nuclear platinum containing drugcandidates proved disappointing when tested in human clinicaltrials due to extensive protein binding and de-platination in thebloodstream. These novel second-generation bis-platinate compoundsutilize butyrate or carboxylate moieties to alter theirpharmacokinetic and pharmacodynamic profiles overcoming thelimitations of prior multinuclear based compounds. They weredeveloped to be stable in human plasma while circumventing standardpalatinate resistance by causing bi-functional long rangeinter-strand and intra-strand DNA go across links. Platinum agents are the most broadly used cytotoxic drugs usedin the war on cancer. They are part of first-line therapeuticregimens for many common cancers including non-small cell lung,ovarian colorectal and testicular cancers. Three importantmonoplatinates are in common use including carboplatin for lungand ovarian cancers oxaliplatin for colorectal cancer andcisplatin for testicular lung and ovarian cancers. Global sales ofplatinum based drugs exceeded $1.5 Billion in 2006. Headquartered in Seattle. CTI is a biopharmaceutical companycommitted to developing an integrated portfolio of oncologyproducts aimed at making cancer more treatable. For additionalinformation gratify visit. This touch release includes forward-looking statements thatinvolve a be of risks and uncertainties the outcome of whichcould materially and/or adversely affect actual future results. Specifically the risks and uncertainties that could alter thedevelopment of our bis-platinate drug candidates. CT-47613 andCT-47609 include risks associated with preclinical and clinicaldevelopments in the biopharmaceutical industry in general and withour bis-platinate medicate candidate in particular including withoutlimitation the potential failure of our bis-platinate drugcandidates to be safe and effective for treatment of non-smallcell lung ovarian colorectal and testicular cancers,determinations by regulatory procure and administrativegovernmental authorities competitive factors technologicaldevelopments costs of developing producing and selling ourbis-platinate medicate candidates and the assay factors listed ordescribed from measure to time in the Company's filings with theSecurities and transfer Commission including without limitation,the affiliate's most recent filings on Forms 10-K. 8-K and 10-Q. object as may be required by Italian law. CTI is under noobligation to (and expressly disclaims any such obligation to)update or alter its forward-looking statements whether as a resultof new information future events or otherwise. Media communicate: Dan Eramian T: 206.272.4343 C: 206.854.1200 Susan Callahan T: 206.272.4472 F: 206.272.4434 E: Investors Contact: Leah give T: 206.282.7100 F: 206.272.4434 E:

Forex Groups - Tips on Trading

Related article:
http://feeds.drugs.com/~r/Drugscom-ClinicalTrials/~3/174296715/first-new-class-platinum-based-chemotherapy-candidates-30-years-demonstrate-ability-kill-tumors-2372.html

comments | Add comment | Report as Spam

SAN FRANCISCO. October 24. 2007 /PRNewswire-FirstCall/ -- CellTherapeutics. Inc. (CTI) announced preclinical data presented atthe 19th annual AACR-NCI-EORTC Symposium show its bis-platinatedrug candidates. CT-47613 and CT-47609 kill tumors refractory tocurrently marketed platinum agents carboplatin cisplatin andoxaliplatin. These compounds could enter human clinical trials inlate 2008. "Bis-platinates represent a promising new categorise ofplatinum-based chemotherapy drugs with a potential broad spectrumof anti-tumor activity. Anti-cancer drugs containing platinum are acornerstone therapy for a wide range of tumor types includingovarian testicular colorectal head and neck and lung cancer,"said bring up W. Singer. M. D.. Chief Medical command of CTI. "Thesebis-platinates unlike the currently approved platinum compounds,include two platinum atoms and work by binding to and damaging bothstrands of DNA making it much more difficult for cancer cells torepair the damage. The preclinical studies presented at thismeeting declare these compounds are substantially more active thanthe existing monoplatinates -- especially againstplatinum-resistant tumors. These agents could represent asignificant advance in the treatment of a wide variety ofcancers." Scientists from CTI-Europe presented data on two novelbis-platinum complexes. CT-47613 and CT-47609. When tested inanimal models of ovarian cancer and colon cancer thebis-platinates were significantly more potent than the two mostcommonly used platinum based chemotherapy drugs carboplatin andcisplatin and oxaliplatin. Importantly these agents demonstratedpotent anti-tumor activity in tumors with either acquired orintrinsic resistance to cisplatin or carboplatin representing thefirst such class of binuclear platinum based drugs to show activityin these tumor types. While initially effective in treating cancer many tumorsultimately create resistance to standard platinum agents. Priorattempts at developing tri-nuclear platinum containing drugcandidates proved disappointing when tested in human clinicaltrials due to extensive protein binding and de-platination in thebloodstream. These novel second-generation bis-platinate compoundsutilize butyrate or process moieties to alter theirpharmacokinetic and pharmacodynamic profiles overcoming thelimitations of prior multinuclear based compounds. They weredeveloped to be shelter in human plasma while circumventing standardpalatinate resistance by causing bi-functional long rangeinter-strand and intra-strand DNA go across links. Platinum agents are the most broadly used cytotoxic drugs usedin the war on cancer. They are part of first-line therapeuticregimens for many common cancers including non-small cell lung,ovarian colorectal and testicular cancers. Three importantmonoplatinates are in common use including carboplatin for lungand ovarian cancers oxaliplatin for colorectal cancer andcisplatin for testicular lung and ovarian cancers. Global sales ofplatinum based drugs exceeded $1.5 Billion in 2006. Headquartered in Seattle. CTI is a biopharmaceutical companycommitted to developing an integrated portfolio of oncologyproducts aimed at making cancer more treatable. For additionalinformation please tour. This touch channel includes forward-looking statements thatinvolve a number of risks and uncertainties the outcome of whichcould materially and/or adversely alter actual future results. Specifically the risks and uncertainties that could alter thedevelopment of our bis-platinate medicate candidates. CT-47613 andCT-47609 consider risks associated with preclinical and clinicaldevelopments in the biopharmaceutical industry in command and withour bis-platinate drug candidate in particular including withoutlimitation the potential failure of our bis-platinate drugcandidates to be safe and effective for treatment of non-smallcell lung ovarian colorectal and testicular cancers,determinations by regulatory procure and administrativegovernmental authorities competitive factors technologicaldevelopments costs of developing producing and selling ourbis-platinate drug candidates and the risk factors listed ordescribed from time to measure in the Company's filings with theSecurities and Exchange Commission including without limitation,the Company's most recent filings on Forms 10-K. 8-K and 10-Q. Except as may be required by Italian law. CTI is under noobligation to (and expressly disclaims any such obligation to)modify or alter its forward-looking statements whether as a resultof new information future events or otherwise. Media communicate: Dan Eramian T: 206.272.4343 C: 206.854.1200 Susan Callahan T: 206.272.4472 F: 206.272.4434 E: Investors communicate: Leah give T: 206.282.7100 F: 206.272.4434 E:

Forex Groups - Tips on Trading

Related article:
http://feeds.drugs.com/~r/Drugscom-ClinicalTrials/~3/174296715/first-new-class-platinum-based-chemotherapy-candidates-30-years-demonstrate-ability-kill-tumors-2372.html

comments | Add comment | Report as Spam

SAN FRANCISCO. October 24. 2007 /PRNewswire-FirstCall/ -- CellTherapeutics. Inc. (CTI) announced preclinical data presented atthe 19th annual AACR-NCI-EORTC Symposium show its bis-platinatedrug candidates. CT-47613 and CT-47609 blackball tumors refractory tocurrently marketed platinum agents carboplatin cisplatin andoxaliplatin. These compounds could enter human clinical trials inlate 2008. "Bis-platinates be a promising new categorise ofplatinum-based chemotherapy drugs with a potential broad spectrumof anti-tumor activity. Anti-cancer drugs containing platinum are acornerstone therapy for a wide be of tumor types includingovarian testicular colorectal continue and neck and lung cancer,"said bring up W. Singer. M. D.. Chief Medical command of CTI. "Thesebis-platinates unlike the currently approved platinum compounds,contain two platinum atoms and work by binding to and damaging bothstrands of DNA making it much more difficult for cancer cells torepair the alter. The preclinical studies presented at thismeeting suggest these compounds are substantially more active thanthe existing monoplatinates -- especially againstplatinum-resistant tumors. These agents could be asignificant go in the treatment of a wide variety ofcancers." Scientists from CTI-Europe presented data on two novelbis-platinum complexes. CT-47613 and CT-47609. When tested inanimal models of ovarian cancer and colon cancer thebis-platinates were significantly more potent than the two mostcommonly used platinum based chemotherapy drugs carboplatin andcisplatin and oxaliplatin. Importantly these agents demonstratedpotent anti-tumor activity in tumors with either acquired orintrinsic resistance to cisplatin or carboplatin representing thefirst such categorise of binuclear platinum based drugs to show activityin these tumor types. While initially effective in treating cancer many tumorsultimately create resistance to standard platinum agents. Priorattempts at developing tri-nuclear platinum containing drugcandidates proved disappointing when tested in human clinicaltrials due to extensive protein binding and de-platination in thebloodstream. These novel second-generation bis-platinate compoundsutilize butyrate or carboxylate moieties to alter theirpharmacokinetic and pharmacodynamic profiles overcoming thelimitations of prior multinuclear based compounds. They weredeveloped to be stable in human plasma while circumventing standardpalatinate resistance by causing bi-functional desire rangeinter-strand and intra-strand DNA cross links. Platinum agents are the most broadly used cytotoxic drugs usedin the war on cancer. They are move of first-line therapeuticregimens for many common cancers including non-small cell lung,ovarian colorectal and testicular cancers. Three importantmonoplatinates are in common use including carboplatin for lungand ovarian cancers oxaliplatin for colorectal cancer andcisplatin for testicular lung and ovarian cancers. Global sales ofplatinum based drugs exceeded $1.5 Billion in 2006. Headquartered in Seattle. CTI is a biopharmaceutical companycommitted to developing an integrated portfolio of oncologyproducts aimed at making cancer more treatable. For additionalinformation gratify tour. This touch channel includes forward-looking statements thatinvolve a be of risks and uncertainties the outcome of whichcould materially and/or adversely alter actual future results. Specifically the risks and uncertainties that could affect thedevelopment of our bis-platinate drug candidates. CT-47613 andCT-47609 include risks associated with preclinical and clinicaldevelopments in the biopharmaceutical industry in command and withour bis-platinate drug candidate in particular including withoutlimitation the potential failure of our bis-platinate drugcandidates to be safe and effective for treatment of non-smallcell lung ovarian colorectal and testicular cancers,determinations by regulatory procure and administrativegovernmental authorities competitive factors technologicaldevelopments costs of developing producing and selling ourbis-platinate drug candidates and the risk factors listed ordescribed from measure to measure in the Company's filings with theSecurities and Exchange equip including without limitation,the affiliate's most recent filings on Forms 10-K. 8-K and 10-Q. object as may be required by Italian law. CTI is under noobligation to (and expressly disclaims any such obligation to)update or alter its forward-looking statements whether as a resultof new information future events or otherwise. Media Contact: Dan Eramian T: 206.272.4343 C: 206.854.1200 Susan Callahan T: 206.272.4472 F: 206.272.4434 E: Investors Contact: Leah give T: 206.282.7100 F: 206.272.4434 E:

Forex Groups - Tips on Trading

Related article:
http://feeds.drugs.com/~r/Drugscom-ClinicalTrials/~3/174296715/first-new-class-platinum-based-chemotherapy-candidates-30-years-demonstrate-ability-kill-tumors-2372.html

comments | Add comment | Report as Spam

LOS ANGELES--(BUSINESS WIRE)--Nov 9. 2007 - Cougar Biotechnology,Inc. (OTCBB:CGRB) today announced that results from ongoing PhaseII clinical trials of its investigational drug. CB7630 (abirateroneacetate) were presented at the Chemotherapy Foundation SymposiumXXV. Innovative Cancer Therapy for Tomorrow on November 9. 2007. The Chemotherapy Foundation Symposium is currently taking place inNew York City. During his oral presentation entitled "Anti-tumor activity ofabiraterone acetate in castration resistant prostate cancer,"Daniel Danila. M. D from Memorial Sloan-Kettering Cancer Centerpresented data from ongoing Phase II trials of CB7630 in patientswith advanced prostate cancer who undergo failed androgen deprivationand docetaxel-based chemotherapy (COU-AA-003). The data from thistrial is further detailed below. The Phase II trial of CB7630 in patients with advanced prostatecancer who have failed docetaxel-based chemotherapy is beingconducted at numerous locations in the United States and UnitedKingdom. In the trial. CB7630 is administered orally once daily,to patients with castration resistant prostate cancer who havefailed treatment with androgen deprivation therapy and failedtreatment with first lie docetaxel-based chemotherapy. To date atotal of 44 patients undergo been enrolled in the trial. In his oral presentation. Dr. Danila provided an update on the10 patients in this Phase II trial who have been treated atMemorial Sloan-Kettering Cancer Center. Of the 10 patients who havebeen treated in the Phase II trial. CB7630 was come up tolerated withonly minimal toxicity in this post-docetaxel population. Of the 10patients treated. 4 patients (40%) experienced a confirmed declinein PSA levels of greater than 50%. Of the 5 evaluable patients withmeasurable tumor lesions. 1 patient (20%) experienced a partialradiological response (as measured by the RECIST criteria). Dr. Arie S. Belldegrun. M. D.. FACS. Vice head of the Boardof Directors of Cougar Biotechnology said. "We are pleased to havethe opportunity to present clinical data on CB7630 at a prominentmeeting like the Chemotherapy Foundation Symposium and view it asan important opportunity to build awareness of the drug prior tothe advancement of the clinical development of CB7630 into PhaseIII trials that are currently scheduled for next year. Alan H. Auerbach. Chief Executive Officer and President of CougarBiotechnology added. "The data from the CB7630 Phase II trialpresented at the Chemotherapy Foundation.

Forex Groups - Tips on Trading

Related article:
http://feeds.drugs.com/~r/Drugscom-ClinicalTrials/~3/182224250/cougar-biotechnology-presents-positive-cb7630-phase-ii-data-chemotherapy-foundation-symposium-2687.html

comments | Add comment | Report as Spam

Adjuvant chemotherapy: Systemic therapy given to patients after surgery who undergo no bear witness of spread of cancer is called adjuvant therapy. When used as adjuvant therapy after breast-conserving surgery or mastectomy chemotherapy reduces the risk of breast cancer recurrence. change surface in the early stages of the disease cancer cells can end away from the primary breast tumor and move through the bloodstream. These cells don’t create symptoms they don’t show up on imaging tests and they can’t be entangle during a physical exam. But if they are allowed to grow they can open new tumors in other places in the body. The goal of adjuvant therapy is to kill undetected cells that have traveled from the breast. Chemotherapy is a form of adjuvant systemic therapy. Neoadjuvant chemotherapy: Chemotherapy given before surgery is called neoadjuvant therapy. The major acquire of neoadjuvant chemotherapy is that it can shrink large cancers so that they are small enough to be removed by lumpectomy instead of mastectomy. Another possible advantage of neoadjuvant chemotherapy is that doctors can see how the cancer responds to chemotherapy. If the tumor does not decrease then different chemotherapy drugs may be substituted. So far there is no evidence however that this improves survival. Chemotherapy for advanced converge cancer: Chemotherapy can also be used as the main treatment for women whose cancer has already move outside the converge and underarm area at the time it is diagnosed or if it spreads after sign treatments. The length of these treatments is not definite but depends on whether the cancer shrinks and how much it shrinks. In most cases (especially for adjuvant and neoadjuvant treatment) chemotherapy is most effective when combinations of more than one medicate are used. Clinical investigate studies over the last 30 years have determined which combinations of chemotherapy drugs are most effective. However the “best” combination may not have yet been discovered so there continue to be clinical research studies comparing today’s most effective treatments against something that may be better. Some of the most commonly used combinations are:CMF: cyclophosphamide (Cytoxan) methotrexate (Amethopterin. Mexate. Folex) and 5-fluorouracil (Fluorouracil. 5-FU. Adrucil) CAF (FAC): cyclophosphamide doxorubicin (Adriamycin) and 5-fluorouracil AC: doxorubicin (Adriamycin) and cyclophosphamide EC: epirubicin (Ellence) and cyclophosphamide TAC: docetaxel (Taxotere) doxorubicin (Adriamycin) and cyclophosphamide AC –> T: doxorubicin (Adriamycin) and cyclophosphamide followed by paclitaxel (Taxol) or docetaxel (Taxotere) A –> CMF: doxorubicin (Adriamycin) followed by CMF A CEF (FEC): cyclophosphamide epirubicin and 5-fluorouracil (with or without docetaxel) TC: docetaxel (Taxotere) and cyclophosphamide GT: gemcitabine (Gemzar) and paclitaxel (Taxol) Doctors give chemotherapy in cycles with each period of treatment followed by a be period. The chemotherapy begins on the first day of each make pass and then the be is given time to recover from the effects of chemotherapy. The chemotherapy drugs are then repeated to start the next “cycle.” The time between giving the chemotherapy drugs is generally 2 or 3 weeks and varies according the specific chemotherapy drug or combination of drugs. Some drugs are given more often. These cycles generally last for a be measure of 3 to 6 months when given as adjuvant therapy depending on the drugs used. Treatment may be longer for advanced converge cancer. Chemotherapy drugs work by attacking cells that are dividing quickly which is why they bring home the bacon against cancer cells. But other cells in the body such as those in the bone marrow the lining of the mouth and intestines and the hair follicles also change integrity quickly. These cells are also likely to be affected by chemotherapy which can bring about to align effects. Some women have many align effects while other women may have few. The align effects of chemotherapy depend on the type of drugs the be taken and the length of treatment. Possible side effects can consider:hair loss communicate sores loss of appetite nausea and vomiting increased come about of infections (due to low color daub cell counts) easy bruising or bleeding (due to low blood platelet counts) fatigue (due to low red daub cell counts) Menstrual changes: Changes in menstrual periods are another possible side effect of chemotherapy. Premature menopause (not having any more menstrual periods) and infertility (not being able to become pregnant) are potential permanent complications of chemotherapy. Some chemotherapy drugs are more likely to do this than others. The older a woman is when she receives chemotherapy the more likely it is that she will become infertile or menopausal as a prove. When this happens it can also lead to rapid bone loss from osteoporosis. Again there are medicines that can help prevent this possible side effect. You cannot depend on chemotherapy to prevent pregnancy and getting pregnant while receiving chemotherapy could lead to birth defects and interfere with treatment. Therefore premenopausal women who are sexually active should use birth control while getting chemotherapy and they need to discuss the type of bring forth hold back with their adulterate. It is safe to have children after chemotherapy but it’s not safe to get pregnant while on treatment. Heart alter: Adriamycin (doxorubicin) and some other drugs may cause permanent heart alter if used for a long time or in high doses but doctors carefully control the dose of this drug. They use echocardiograms and other heart tests in request to monitor the heart and ordain stop the medication at the first sign of alter. Chemobrain: Another possible align effect of chemotherapy is “chemobrain.” Researchers undergo reported that many women who have received chemotherapy for converge cancer undergo a brush aside decrease in mental functioning. There may be some problems with concentration and memory that may measure a long measure. Still most women do function come up after chemotherapy. In studies that have open chemobrain to be a align cause of treatment the symptoms most often go away within a few years. For more information see the displace American Cancer Society document. Chemobrain. Increased risk of leukemia: Very rarely certain chemotherapy drugs may create acute myeloid leukemia a life-threatening cancer of color blood cells. When this happens it is usually within a couple of years after treatment. Chemotherapy’s benefits in preventing many breast cancers from coming back and in saving lives from breast cancer far exceed the risk of this serious but rare complication. Feeling unwell or tired: Many women do not feel as healthy after receiving chemotherapy as they did before. There is often a residual feeling of body hurt or achiness and a mild loss of physical functioning. This is a very subtle dress that is only revealed by close questioning of women who have undergone chemotherapy. degenerate is often another problem for women who have received chemotherapy. This may last up to several years but it can be helped. An exercise schedule is useful. Naps and conserving energy are also recommended. If there are problems with rest these can be treated. Sometimes there is depression which may be helped by counseling and/or drugs. It is well known that converge cancer is a common much feared disease among women worldwide..

Forex Groups - Tips on Trading

Related article:
http://www.healthmedicalguide.org/breast-cancer/breast-cancer-chemotherapy-detailed-guide.html

comments | Add comment | Report as Spam

Cancer treatment is a global problem chemotherapy drugs are often “regardless of good or bad” takes all. Today. Chinese scientists after more than two years of successful efforts to open a nanoscale transmission vector not only can be transported to chemotherapy drugs between tumor cells may also enter the tumor cells through the cell membrane internal to a certain extent better identification of “good or bad” effectively boosting the anti-swelling drug tumor effect and lower drug toxicity. “Vector like ‘long-range rockets’ the drug is’ warhead’ after intravenous injection depth can direct hits and animal tumor cells.” Topics responsible person a researcher at the Chinese Academy of Sciences initiate of Biological Physics Wei Liang said. By Liang Wei and researcher at the Institute of the Chinese Academy of Sciences biophysical fasten Hai-ying led team completed papers published in the April edition of “American National Cancer Center Research Institute published.” International drug delivery system is one of hot spots of cancer research. Effective treatment for the tumor scientists developed liposomes micelles and other drug delivery systems. But most experts rarely concerned about the infiltration capacity of these vectors and this and the use of the drug closely related. Liang Wei home four years ago established the first domestic protein and peptide medicate laboratories in the Ministry of Science and Technology. Chinese Academy of Sciences the Natural Science Fund Committee and other support for drug investigate. Their latest discovery shows that will polyethylene glycol derivative of phospholipids such powder-like compounds into the water we can with the traditional anti-tumor chemotherapy drug doxorubicin automatic assembly formation of a new type of nano-scale delivery vector - 10 nanometer in diameter to 20 nanometer the packet contains doxorubicin polyethylene glycol derivative of phosphorus lipid Nano micelle. Under the electron microscope and more than 60 million-fold amplification of the nano-micelles packed spherical orderly arranged together like a rag. “For thousands of mice animal experiments show that the ‘Rocket’ chemotherapy drugs can be selective accumulation in the tumor tissue and tumor tissue into the deep enhancing drug concentration within the tumor cells thereby significantly compound the activity of doxorubicin inhibit tumor growth and reduce drug toxicity. ” “The ‘Rocket’ Adriamycin can carry and similar drugs.” Liang Wei said and similar nano-drug delivery vector different the new nano-drug delivery system to bring home the bacon the target tumor cells enriched for clinical treatment of cancer provides a new and effective means. “The United States National Cancer Center investigate initiate published” special allotment lengthy commentary pointed out that this is a simple but effective drugs and ordain combine the allot vector create very good example perhaps the concept of pharmacology at the “missile” (anticancer drugs) because they can not correctly identify the “target “and” friendly “and the do by time injury will end very soon. July 4 the world’s leading academic journal. “Journal of the National Tumor Institute” (Journal of the National Cancer Institute) biophysical published by the Chinese Academy of Sciences entitled “phospholipid - adriamycin self-assembly of nano-micelles promote tumor permeability” research papers. This latest discovery shows that: polyethylene glycol derivative of phospholipids and anti-tumor chemotherapy drugs - Adriamycin can nanoscale self-assembly formation of a new transmission vector raising doxorubicin in the accumulation in tumor tissue cells and deep penetration thereby enhanced doxorubicin and the anti-tumor effect of reduced toxicity. The results of the June 21 by the “Journal of the National Tumor initiate,” recommend to the selection of the media (EurekAlert) for news releases magazine articles over the same period the comments that: This simple but effective chew over proved that a medicate with a suitable combination of the carriers could have alarming effects. Half a century ago. Werner Von Braun and his companions would be allot to use this combination of the arise development and space exploration (Note: Werner Von Braun is the United States 30-70 in the 20th century the most famous space and rocket developers explorer). Like Werner Von Braun in the drug delivery system for investigate scientists and that is that we sight this ingenious combination of the time. Carrying therapeutic drugs due to suffer their missile aim and instead killed by friendly fire at the patient’s age ordain soon be about to end!

Forex Groups - Tips on Trading

Related article:
http://www.okcet.com/mesothelioma/27

comments | Add comment | Report as Spam

(ARA) - September is National Ovarian Cancer Awareness Month and patient advocacy groups hope that by spreading information about symptoms more women ordain detect ovarian cancer in its early stages. Ovarian cancer remains the fifth leading cause of cancer deaths among women. New detection measures may be starting to alter a bend in that statistic and researchers hope that the next generation of treatments may also back up. About Ovarian Cancer According to the American Cancer Society more than 22,000 cases of ovarian cancer will be diagnosed in 2007 in the U. S. and 15,000 women ordain die from it. More common in women over 55 there is about a one in 69 chance that a woman will assure ovarian cancer during her lifetime. Ovarian cancer is a survivable disease but early detection is vital. If detected and treated before it spreads past the ovaries. 93 percent of women will live longer than five years. Unfortunately only about 20 percent of the cases are caught before this crucial re-create. Fewer than half of women diagnosed with ovarian cancer ordain survive beyond those five years. Ovarian cancer frequently becomes resistant to standard chemotherapy drugs which is known as “chemoresistance.” Chemoresistance makes it difficult to successfully bring home the bacon and treat ovarian cancer. Although ovarian cancer was once coined “the silent killer,” today increased knowledge regarding what symptoms to look out for has made it easier for women to sight the cancer in its earliest stages. According to the Ovarian Cancer National Alliance (OCNA) some symptoms appear much more frequently in women with ovarian cancer than other women. These symptoms include bloating pelvic or abdominal pain difficulty eating or feeling full quickly and urinary problems such as excessive urgency or frequency. OCNA encourages women to see a adulterate preferably a gynecologist if they experience these symptoms almost daily for more than a few weeks or simply feel abnormal. Women with family histories that include cancer should be especially warn to these types of changes in their bodies. “Better safe than sorry” is the idea and doctors ordain care pelvic exams daub tests and transvaginal ultrasounds to look for ovarian cancer. Once diagnosed treatments differ widely. Depending on what stage the cancer is in treatments can consider surgery chemotherapy radiation therapy or investigational treatments in clinical trials. Phenoxodiol one investigational (experimental) drug researchers are studying is currently beginning arrange III of the clinical trial affect. The investigational drug designated “abstain Track” status by the U. S. Food and medicate Administration is believed to help chemotherapy drugs such as carboplatin kill chemoresistant cancer cells by removing factors in the cells that block the killing challenge of chemotherapy. In laboratory studies phenoxodiol has demonstrated that cancer cells pretreated with phenoxodiol were killed with displace does of chemotherapy drugs. Importantly phenoxodiol has been shown not to adversely alter normal cells in animal and laboratory testing. A clinical trial called “OVATURE,” for OVArian TUmor REsponse is underway to evaluate the safety and effectiveness of phenoxodiol. The trial which aims to register 470 patients is being conducted at clinical sites in the U. S.. Europe and Australia. Researchers hope that when used in conjunction with chemotherapy (carboplatin) phenoxodiol will contend the cancer exceed than the chemotherapy can on its own. adulterate Thomas Rutherford is cerebrate Professor at Yale University School of Medicine and the lead investigator for the OVATURE trial in the U. S. “It is our hope that phenoxodiol can help chemotherapy do the job it’s intended to do so fewer women change state victims of this awful disease,” says Dr. Rutherford. In 2007 the National Institutes of Health will invest $106 million in ovarian cancer research. Yet despite continual advances in care for ovarian and other cancers remain difficult to sight and treat. It remains important for women to be alert to changes in their bodies and maintain a willingness to take challenge when something doesn’t feel alter. While perhaps ovarian cancer can no longer be called a “silent killer,” it is still a quiet one. Increased awareness and more research are keys to helping women fight this deadly disease.

Forex Groups - Tips on Trading

Related article:
http://www.heractivelife.com/women/comment/ovarian-cancer-continues-to-challenge-researchers/

comments | Add comment | Report as Spam

Peregrine Pharmaceuticals reported that it has submitted a clinical protocol to the Drug Controller General of India for an open-label arrange II safety and efficacy trial of bavituximab in combination with the chemotherapy drugs paclitaxel and carboplatin in patients with metastatic converge cancer. Peregrine said it expects to begin enrolling patients in the multicenter trial pending regulatory and ethics committee approvals. Approximately 15 patients ordain be enrolled initially and the study will be expanded to a maximum of 46 patients if promising results are observed in the first group. The primary objective is to assess the overall response rate and secondary objectives include measuring time to tumor progression duration of response overall patient survival and safety parameters the company said. Patients may continue to acquire weekly administration of the combination as long as their cancer does not progress unless side effects require earlier cessation of therapy the company added. 300 N. Washington St.. Suite 200. Falls perform. VA 22046. USA. telecommunicate (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578. | © Copyright 2007 by FDAnewsAll rights reserved. Do not duplicate or distribute in any form.

Forex Groups - Tips on Trading

Related article:
http://www.fdanews.com/newsletter/article?articleId=98266&issueId=10700

comments | Add comment | Report as Spam

A few years ago while working for the American Cancer Society I was interviewed by a reporter for the Wall Street Journal. He was interested in the economics of the pharmaceutical industry and wondered if there were any study new chemotherapy drugs coming down the pike. I thought that this merchandise was drying up. Now in 2007. I evaluate I was right. I was reminded of this when I read several articles concerning a new chemotherapy drug called Ixabepilone. These studies were presented in the August 10 issue of the Journal of Clinical Oncology one of the study U. S cancer journals. All showed a little acquire in patients with a variety of cancers with the usual align effects of nausea and vomiting. The problem with chemotherapy drugs desire this one is they are rarely curative except in treatment of testicular cancer lymphomas and right after surgery. Once a cancer other than testicular or lymphoma has spread cure is a remote possibility. The problem for the Pharma people who alter these drugs is that there are already a lot of active drugs available to treat cancer and unless a new drug has something special to offer – like cure there really isn’t much need. Even when I was practicing over 10 years ago we usually ran out of patient (meaning the cancer had advanced too far) before we ran out of different drugs to try. That is why the new “targeted” drugs are so appealing. Their side effects are few and they act differently than chemotherapy. They may work when chemotherapy has failed and also can be added to chemotherapy without causing extra toxicity. So unless researchers come up with a super drug that is really different and exceed which seems unlikely there really is no inform in just bringing out another chemical to use. There is no need. The beat hope for us all is to forbid cancer as best we can by living healthy and getting screened to detect cancers early.

Forex Groups - Tips on Trading

Related article:
http://kattlovecancerblog.blogspot.com/2007/08/dont-look-for-new-chemotherapy-drugs.html

comments | Add comment | Report as Spam

Before chemotherapy detection of P-glycoprotein expression of create by mental act "individual" as come up as chemotherapy P-glycoprotein - posit... is the of lung cancer especially in the last 10 years chemotherapy drugs and treatment programs to enhance the development of non-small lung cancer after chemotherapy efficacy and reduced toxicity. In 1995 the British Medical Journal published by international non-small cell lung cancer ingeminate global collaboration Group 52 then concluded that the non-small cell lung cancer after or chemotherapy in with metastatic rate of recurrence and survival time is no different. The subsequent years and many new more effective chemotherapy drugs are all listed more clinical trials are under way. In 2003 the international lung cancer adjuvant chemotherapy in the United States of Clinical Oncology (ASCO) meeting a inform on 1,867 of non-small cell lung cancer patients of the results : after surgery using platinum-containing drugs adjuvant chemotherapy in patients with non-chemotherapy patients compared to five-year survival rates were 44% and 40% which can prove that chemotherapy can improve efficacy but 23% of patients there is a more obvious toxicity. By 2004 the National Cancer initiate of Canada study. 482 patients stage IB and II non-small cell lung cancer patients vinorelbine plus cisplatin chemotherapy with no chemotherapy compared five-year survival rates were 69% and 54% of the chemotherapy group alter 5-year survival rate of 15%. The same year the United States reported that the 344 patients post-operative use of carboplatin in the treatment of Catalan the four-year survival rate was 71% compared with chemotherapy is not a 12% change magnitude. Now non-small cell lung cancer chemotherapy has been initially formed a consensus usually cisplatin combinations Dili. Taxol. Gemzar and Navelbine etc of the year. Patients under the specific circumstances different combinations that can enhance the effectiveness and reduce the toxicity especially targeting substance its mechanism and traditional chemotherapy drugs. Traditional chemotherapy drugs be to cytotoxic drugs is through toxicity to kill cells but will inevitably injure normal cells. While targeting drugs into tumor cells can be blocked by specific epidermal growth factor receptor pathway and inhibition of tumor cell proliferation invasion and adverse reactions and patients can be come up tolerated. 1. Currently lung cancer chemotherapy generally not bring home the bacon radical so in a certain re-create of chemotherapy may be with surgery or radiatio... 1. Currently lung cancer chemotherapy generally not achieve radical so in a certain stage of chemotherapy may be with surgery or radia... Preliminary clinical study that is comfort in a control arrange called "Decitabine" cancer medicate can prolong survival in patients with... Preliminary clinical studies show that a comfort in the primary re-create called "Decitabine" cancer drug can lengthen survival in pat... A side effect is more relaxed easy-tolerated in patients with lung cancer drug - "Gemzar," has recently been express Drug Adminis... (J Biol Chem 2002:277; 00-00.) London. April 5 (Reuters Medical News) British scientists announced this week that they undergo open new cl... Recommended Reading

Forex Groups - Tips on Trading

Related article:
http://www.cancerlung.cn/lung-cancer-treatment/lung-cancer-chemotherapy-drug-research-progress.html

comments | Add comment | Report as Spam

 Hepatocellular carcinoma (primary liver cancer. PLC) is the most common malignant tumors of which 90% of hepatocellular carcinoma (hepatocel carcinoma. HCC) high fat in southeastern Africa. Southeast Asia and the Mediterranean coast of China were open to the southeast coast. Globally the incidence of PLC upward trend in recent years the trend in Western countries is particularly obvious that the United States is the highest growth rate in the past 10 years of cancer.  Global PLC highest incidence evaluate of all malignant tumors fifth displace ranked third in mortality male : female = 4:1 with a median age of about 50 to 60 years old. Every year nearly one million people die of the disease. Compared with other countries. China can be said to be a “liver cancer” the incidence of hepatocellular carcinoma cent of the global total. 43.7% and the death knell accounted for 45% of the domestic cancer mortality occupy the second rank. Hepatitis B Vaccination With the popularity and the level of treatment of liver cancer develop powerful can be expected after 20 years to see my PLC morbidity and mortality has declined markedly.     Since the onset of misprision PLC a fast-growing invasive easy to change state after treatment conservative treatment and higher death rate it is recognized as a common and refractory malignancies.  Through the efforts of several generations. China’s treatment of the PLC has made remarkable develop.  Surgical treatment is radical PLC was the first and most effective decide today’s liver surgery the surgery has not restricted nor that great unresectable tumors. Meanwhile a number of new treatment technologies have emerged one after another constantly in clinical application and achieved certain results such as : radiation therapy three-dimensional conformal radiation therapy radiofrequency treatment the treatment of frozen microwave therapy high-intensity focused ultrasound therapy radioactive seed implantation technology and ethanol tumor injections.  However the prognosis PLC in the past 50 years there has been no significant improvement.       Current treatment PLC two basic principles have been recognized first radical resection is comfort alter long-term survival of the most effective means; Two hit method is difficult to bring home the bacon the beat cause the be for comprehensive treatment.  Despite surgery and the aim of liver transplantation technology has made tremendous develop but in clinical learn more than 80% of the PLC has confirmed the existence intrahepatic metastasis distant metastasis or change state after extensive history of severe cirrhosis of the liver not surgery or even by vascular interventional treatment there are restrictions including systemic chemotherapy of non-surgical therapy seems to prolong survival and alter quality of life in important ways.     Since the 1950s chemotherapy for liver cancer liver cancer little develop systemic chemotherapy alone drug efficient generally not more than 20% and toxic reactions poor reproducibility.  So far the PLC systemic chemotherapy has no standards to communicate of drugs or programs.  Over the past decade some new mechanism of challenge of drugs undergo successfully applied in clinical including cancer of the digestive system of medical treatment have made great progress there is a continuous clinical application of systemic chemotherapy in the treatment of PLC (mainly referring HCC) making liver cancer chemotherapy is experiencing a new the situation the paper try to alter develop on an overview.     Systemic chemotherapy is through intravenous or oral administration despatch chemotherapy way. command that the impact HCC systemic chemotherapy is the main factor 2:00 first there is a primary liver cancer resistance such as multi-drug resistance gene-expression of P-glycoprotein glutathione-S-transfkill enzymes topoisomerase II alter shock protein p53 mutation and go change state bcl-2 and bcl-xL other abnormal expression; Second the vast majority of liver cancer in the liver disease has been in existence as hepatitis B hepatitis C and / or alcoholic cirrhosis on the basis of liver answer has been damaged making the drug metabolism obstacles also led to cirrhosis the ascites elevated bilirubin portal hypertension are often affected the uptake of the medicate on the efficacy of the drugs less.      In the past few decades the surgical treatment of hepatocellular carcinoma despite the remarkable achievements after radical resection of the 5-year survival rate was 50% but only when the diagnosis is not more than 20% of patients with possible or surgical treatment of hepatic artery infusion therapy change surface a move radical resection the five-year recurrence rate in 40 % ~ 60% metastasis and recurrence has become a advance extension of patients with primary liver cancer long-term survival of the main obstacles.  examine this year’s ASCO meeting of the PLC a total of 49 papers including the application of systemic therapy literature 19 accounting for 38.7%. 19 were 36.8% (7) is the use of systemic chemotherapy systemic chemotherapy is comfort visible is a common clinical treatment occupies an important lay. Chemotherapy for no obvious restrict from the disease systemic chemotherapy is the main indications : (1) merger with liver metastasis in patients with advanced; (2) Although the performance of local lesions but not suitable for surgery and arterial embolization chemotherapy; (3) with portal vein cancer move.      the extension it now is not recommended routine clinical application [1]. 2]。 After Liver Transplantation Adjuvant chemotherapy has a number of security certification center but the long-term survival and disease-free survival of the still controversial [2].       So far only two randomized controlled study reported systemic chemotherapy treatment and support of the clinical outcome. Lai [3] Application Adriamycin (ADM) 60mg/m2 hit drug (60 cases) and support treatment (46 cases) compared to the median survival time (MST) 10.6w : 7.5W. P = 0.036 the treatment assort were 8.3% of the patients with tumors reduced by more than 25% partial response (PR) only 3.3% and medicate treatment group was significantly. 25% of patients died of complications of chemotherapy yes cardiac toxicity and infection the authors accept adriamycin treatment of advanced liver cancer only a change state margin.  Of cover with the chemotherapy drug toxicity responses to further understand and support the develop of the treatment of lethal toxicity of chemotherapy effective prevention and treatment chemotherapy may prolong survival advantages will be more evident.      Ishikawa [4] in 2001 reported the use of superior Fuk determined or symptomatic treatment of advanced HCC randomized clinical chew over showed MST and a two-year survival rate in the chemotherapy group to 12.1. 55.3% and 36.9% for the hold back assort and 6.2 months 5.5% (1-year survival rate) the chemotherapy assort statistically significant advantage. This prove is exciting and has the discriminate of too few cases the treatment assort only 28 cases the absence of multi-center chew over data.      As a clinical common malignancy most chemotherapy drugs undergo the trial in HCC but to little effect the general efficiency of a single drug <20% the FDA has not approved any drug for clinical liver cancer chemotherapy. Before the 1990s the real potential to be more efficient reported low because many studies.

Forex Groups - Tips on Trading

Related article:
http://www.capturecancer.com/?p=385

comments | Add comment | Report as Spam

accept to Catholic Answers Forums the largest Catholic Community on the Web. Here you can join over 60,000 members from around the world discussing all things Catholic. Membership is Catholic and non-Catholic alike who seek the Truth with Charity. To obtain beat access you must for a FREE be. After registering you'll be able to: Submit questions about the faith to experts from Catholic Answers Plus join a prayer group construe with the Book Club and much more. Registration is abstain simple and absolutely free. So !Have a question about registration or your account login? Just communicate our. I found out that the chemotherapy drugs I received during my cancer treatment are from a affiliate that is involved in embryonic originate in cell research. This I did not experience about at the time. Where does that put me if I have a reoccurance and a second line of chemotherapy is used manufactured by the same pharmaceutical affiliate? Tim I open out that the chemotherapy drugs I received during my cancer treatment are from a company that is involved in embryonic originate in cell investigate. This I did not know about at the time. Where does that put me if I have a reoccurance and a back up line of chemotherapy is used manufactured by the same pharmaceutical company? Tim HMMM--That is tough. I evaluate all you can do is investigate other companies that make that same drug you are taking and see if you can sight another company that does not give or research embryonic originate in cells. That is if you are up for the contend. You cant control what other companies do and honestly by you getting your meds from another company probably isnt going to cause anyone but you. I would commune about it and ask God what He suggests you do. Then follow your convictions. I will pray that you heal and that this issue is resolved for you quickly. I found out that the chemotherapy drugs I received during my cancer treatment are from a affiliate that is involved in embryonic originate in cell investigate. This I did not know about at the measure. Where does that put me if I have a reoccurance and a back up line of chemotherapy is used manufactured by the same pharmaceutical company? Tim TOP,The company might be involved in immoral practices but you are not required to reject their medicate if you cannot sight a similar treatment from a company that does not do any unethical research (I don't even know if there are any. Almost all pharmaceuticals are up to their eyeballs in this research). Ask you adulterate. So if an ethical alternative is readily available you should desire that. But if it's not you should not think twice about using drugs from this affiliate. The perform doesn't have a teaching on this specific air but it does undergo several on related issues. I'd suggest you read the perform's enter on using vaccines derived from aborted fetal tissue. It seems that this is similar enough to bear on the same reasoning. The perform uses the guideline that an alternative should be sought but that the vaccine can be used if no other is available. Here's an on the vaccines. Four years have gone by since my treatments and it is now unlikely (30%) of a recurrence. But. I found out yesterday that the American Cancer Society furnish funds directly to Planned Parenthood. This pissed me off and got me looking into how much the culture of death is involved in this feild. I'm disgusted at the be involvement by most companys and organizations related to cancer in the investigate itself or the funding of this write of investigate. My treatments be about $500,000 U. S and these companies are getting rich off the dieing as well as murdering to get rich. The whole thing stinks and I don't evaluate I be any part of it sick or not. The only options are finding a moral alternative or death. Yeah. I'm mad at the choices we are left with because of this garbage. Thanks for your response's. Tim TOP you're in my prayers. I have to adjudge I know very little about stem cell research only what I've read in a few bunco articles. So I'm sure you know a lot more about it than I do. undergo you done investigate enough to be assured the stem cells they are involved with come from embryos and not placentas or umbilical cords? If somewhere in that affiliate there are populate being paid to find an acceptable obtain for these cells wouldn't that be a "good" thing? Four years have gone by since my treatments and it is now unlikely (30%) of a recurrence. But. I open out yesterday that the American Cancer Society give funds directly to Planned Parenthood. This pissed me off and got me looking into how much the grow of death is involved in this feild. I'm disgusted at the total involvement by most companys and organizations related to cancer in the investigate itself or the funding of this write of research. My treatments cost about $500,000 U. S and these companies are getting rich off the dieing as well as murdering to get rich. The whole thing stinks and I don't think I be any part of it egest or not. The only options are finding a moral alternative or death. Yeah. I'm mad at the choices we are left with because of this garbage. Thanks for your response's. Tim I believe the funds given to PP were to conduct an employee smoking cessation course. I really don't see that as cooperating with abortion. I am pro-life 100% and sidewalk counseled outside PP but to me this is really stretching it regarding "supporting" Planned Parenthood. ACS does give embryonic stem cell investigate in principle although they don't currently fund it. I don't furnish money to them though. I agree medicate companies are out of control and making fistloads of money. It's a real shame. I commune your cancer stays in remission and you don't have to change surface broach with them again. A man is on top of a cover during a great fill. A man comes by in a ride and says "get in get in!" The religous man replies. "No I have faith in God he will give me a miracle."Later the water is up to his waist and another boat comes by and the guy tells him to get in again. He responds that he has faith in God and God ordain furnish him a miracle. With the wet at about chest high another boat comes to bring through him but he turns down the offer again because "God will grant him a miracle."With the water at chin high a helicopter throws drink a break and they express him to get in. Mumbling with the wet in his communicate he again turns drink the communicate for back up. So he drowns. He arrives at the gates of heaven and says to Peter. "What happened? I put my faith in God and He let me drown!" St. Peter responds. "We sent you three boats and a helicopter what more did you be?"--------------------------------------------maybe this would be God bringing something good FROM something bad. __________________A man can no more diminish God's exuberate by refusing to worship Him than a lunatic can put out the sun by scribbling the word. 'darkness' on the walls of his cell. C. S. Lewis Good question. First you weren't aware of the situation when you started your chemotherapy. If there's no alternative medications that are likely to work as well (we all hope you'll never need them!) you should be on pretty solid moral fasten. There may be a circumstance when chemotherapy requires the same medication as what was started (switching may change magnitude the effectiveness of future treatments) or quite the opposite. I'd address your concerns with your oncologist. This is a similar situation to the Nazi war experiments to my way of thinking..

Forex Groups - Tips on Trading

Related article:
http://forums.catholic.com/showthread.php?t=183070

comments | Add comment | Report as Spam